The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Well, there is no doubt in my trust in where this company is going. I am not interested in Skin as this is just one of many potential clients. Avacta have some huge projects in the pipeline including the imminent stream of Covid19 testing options as well as a potential strong and seriously exciting virus blocker. However there is much future potential in multiple diagnostic opportunities which once Avacta actually have product coming through BBI Solutions and Abingdon Health they will have a faster path to market.
The pre|CISION cancer treatments once phase I Clinical trials are underway with results returned with positive progress will unlock the company to very interesting stage of progress. Yes I may sound like a broken record but it is a fact that one development will bring much more to Avacta. Sure we could see very strong growth over the coming months and some mouth watering returns, but that will pale into insignificance compared to future returns on pre|CISION AVA6000 as well as others.
The other partnerships will bring huge potential returns too.
As a 2 to 3 investment we should all be very excited. Don't be inpatient here!
Cheers, Rich
https://avacta.com/about/
@mortgagefreeman - I am intrigued are you really invested here? You question everything with a negative approach. You wonder at peoples optimism on the potential here.
I suggest you rewatch the presentation from the 6th May at the business update and outlook.
Cheers, Rich
Zztop, it means that Affimer technology is progressing into multiple avenues which will be very valuable in many aspects of therapeutic and diagnostic Medicine which will be very valuable to future developments.
That is all most people need to understand.
Cheers Rich
https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cbic.202000585
No, unfortunately I can't. I just know that there are orders for that amount of containers for spittle which will be used for accurate Covid19 testing. If the NHS are expecting to collect that amount of containers then there must be a test which they will be supplying this into. That is not for PCR is it? They use swabs.
You can be sure when the numbers are in place, the order books will be full. I am totally confident that Avacta will provide the best S&S in the diagnostics world and it will be a world beater.
I expect we will learn much more next Monday and have an update on the timing on the POC LFA test.
In the meantime we are still expecting BAMS and that can and should still give an huge boost to testing capacity with the right machines and lab capacity being made available. Don't forget saliva is the key carrier for the Covid19 virus and from samples of saliva spittle the S&S is much easier to get 100% right. This brings me to another part required which is a vessel to store spittle. There are companies in production of these already with orders over 100 million units! A fact.
So I think we are close to much more news and remain totally happy with my investment here!
Cheers, Rich
There is a lot of people talking about the tests and validation here. We are can see one massive market. I work in manufacturing sector and have multiple access in to medical device manufacturing businesses. For Avacta the test is made up of three key components.
1. The Affimer combination made and produced by Avacta and this is the critical bit! It determines the sensitivity and specivity of the test.
2. The membrane technology which comes from Cytiva which is very specialised hence there key involvement
3. The casing - this is an injection moulded component made of polymer, usually chosen to match the test use.
The first two are specialist technologies which are already covered. The third sounds easy. But this is a critical part and needs specialist tooling. The moulded part will come from a multi cavity tool with usually 8, 16, 32 or 48 cavities. The tool would be split into a male and female part (front and back if you like). The tooling for such projects is typically in the cost range of £400K to £600K per tool. One tool could potentially run at 360 cycles per hour. If we take a 16 + 16 tool (32 cavities) then you would produce 5760 pairs per hour or 138,240 per day. A moulding machine to run that tool, costs with equipment around it around £350K per machine. There are already multiple manufacturers who will be making these parts for existing lateral flow diagnostic testing. But, the challenge is increasing the number of machines and tooling. This is a key area and the sub-suppliers will be to companies like BBI and Abingdon Health. The question for these manufacturers is after the investment how long will this product be required and who is funding these projects. To make 10 million tests per week, you would need 72 sets of machines and tools in multiple suppliers.
You can be sure there will be multiple companies building capacity to do just this. Part of the time frame here is the lead-times of specific tooling which can be up to 16 weeks. Only Avacta, BBI and Abingdon know how big there current supply chain is to fulfil the huge demand required for all the current projects. These details are very important to understand in the current situation. The tools can be made from a number of high quality tool makers around the world, so you can be sure that everything is being done to ensure they have capacity to expand. I think any delays being seen are most likely due to this capacity requirement. Avacta will need based on the target S&S requirements millions of test per day to meet demand and once the product is not only out there but showing it can be relied on in the field a huge ramp up.
The UK market alone is currently off the scale, let alone the needs across the whole planet.
This hopefully helps people understand better the full picture of just the cases for LFT.
Cheers, Rich
The Introduction:
Avacta is a Biotech company with two operating segments, the Therapeutics operations based at Avacta’s Cambridge site (pre|CISION™ ) and the Diagnostics operations ( Affimer® ) in Wetherby.
The Expertise!
Avacta has two key areas - Affimer® technology a uniquely developed technology which is used as a diagnostic to find virus’s based on a human protein called Stefin A. The Affimer® platform is Avacta’s proprietary therapeutic platform with its intellectual property covered by several patent families.
Projects:
Affimer® technology projects with LG Chem just on licensing can be worth up to $310 million.
ADC project backed by Astra Zeneca for PBD Warheads - loaded affirmer drugs $500 million.
A joint venture in South Korea with Daewoong a leading Korean pharma company, to develop the next generation of cell and gene therapies, incorporating Affimer proteins to enhance the immune-modulatory effects. Avacta holds 45% of the business but the finance is provided by venture capitalists where the market potential is still too large to actually pinpoint as there are NDA's in place so the market information can't be shared. Huge potential!
The huge project with Affimer® technology with Moderna which again will give drug deliveries for mRNA delivery is still progressing. Huge potential!
Affimer® technology to detect Covid19 using Antigen tests the partners are Cytiva (LFD) and Adeptrix (BAMS) with distribution through 4 Mass Spectrometer suppliers (both close to production)
There are existing 5 other Affirmer evaluations progressing, 17 other projects already delivered for evaluation, and a further 7 development projects initiated! Just the start!
The Expertise:
Avacta’s pre|CISION™ technology can be utilised in a drug conjugate linker or to generate chemotherapy pro-drugs that are only activated in the tumour.
When added to a chemotoxin, the pre|CISION™ substrate prevents the chemotoxin from entering cells and therefore renders it inert until the substrate is cleaved in the tumour microenvironment. Using this pro-drug approach, the systemic exposure to the chemotoxin is dramatically reduced, and the safety and therapeutic window of these powerful anti-cancer treatments are improved.
The projects:
pre|CISION™ partnerships which are looking to start with opportunities in AST, Breast and Ovarian cancer the EU/ US market potential is around $1.5 billion.
Research Opportunities for the reader:
Broker Note: https://mcusercontent.com/d9ebd7c1aa0f3dbc5fab42eca/files/72d24b8a-baa2-4776-a5a7-935a437b37ab/AvactaGroupplc_7_9_2020_FINAL_BG.pdf
The last Presentation:
https://youtu.be/DzoxXCB4or0 - from 1hr 33min 50 seconds
Latest from Avacta: https://avacta.com/news/
and https://avacta.com/investors/documents-presentations/
A good read from a well-known researcher is found here:
https://aimchaos.files.wordpress.com/2020/06/avacta-group-update-ii-part-iii-1.pdf
Investment for 2020 and beyond , it certain
I am not new here, but building a very nice position. Long term prospects are exceptionally promising.
So far bought over £50k’s worth.
Very happy to hold for a minimum of 2 years.
Hope others see the opportunity.
Cheers Rich
Diplomat65, I don’t think you will have to be patient for a solid return.
People keep asking why I am so positive.
Let’s put this in perspective.
Bank account gives 0.01% interest
Investment account gives 0.25% interest
Average fund gives 5% annual growth
Fundsmith an ‘A’ star fund will give 20% growth
Avacta has seen growth of 683% in the last year.
This is nothing when in a years time we could have a share price between £4 to £20!
I think a little patience for one of the most important Covid19 testing products coming to market is going to be massive.
Cheers Rich
Next Monday we have a massive presentation to investors and potential investors in Avacta. The company will be doing everything to have a very strong story to present yet again. We only have to look back to May to see that presentation to know how well that painted the picture. They have made massive progress since then. The market is now significantly larger and growing way too quickly.
Anyone buying in at these prices will surely see a massive return.
Currently we are awaiting news of first production from both BBI and Abingdon Health, with expectation of production capacity increasing. If we see another partnership announcement especially if in either Europe or / and the US it would not be surprising. Then I think investors will really se the huge direction ahead.
This is a much bigger potential than any of us really thought. The power to the market of this simple test with fast results is beyond what every government could dream of.
I expect huge growth and a strong market position for all our tests. Potentially only 4 days till a very interesting revelation!
Time for some more buying I think!
Have a good day.
Cheers,
Rich
Well Yorkshirepragma, stage 1 is to get approvals and production and sales from BBI and Abingdon Health, that will be the perfect start. Orders and production ramp up is phase 2, although orders is about the most sure thing right now that we could imagine. They will sell every test they can make in the next 12 months at least. Be that 1 million or 1 billion!
BAMS, POC LFD and of course ELISA!
Avacta will be a globally significant player.
Successful supplies of tests will be key, S&S critical and speed of results will safe the NHS and every industry billions. Our tests are that important.
Cheers Rich
It is good to see that Avacta are making sure they present all aspects of the business in totally professional way! It looks crisp and fresh and high quality. Given the world they operate in and the multiple partnerships they have already in progress and the potential moving forward. I am delighted with the totally professional look and crisp presentations!
Great work Avacta. https://avacta.com/
I expect a lot of move around over the next few weeks as the Covid19 situation is clearly heading in the wrong direction. Avacta are closer than ever to offering multiple testing opportunities for the masses and when they do then we can expect a valuation much, much higher than today.
Have a good week all! And no, I am not selling!!
Cheers, Rich
K.Invest - I still hold BMN! Which I have held since March 2017 and will likely hold at least till 2030! If you have issues with your own investment strategy, then look in the mirror! You buy, you sell! Your choice that is your decision!
Share chat boards are to share information, people have to make all their own decisions!
There are times when you have to make a decision to sell (partial or complete holding) for reasons either relating to the companies direct, global influence or a clear change in investment strategy! You may then chose to reinvest in that company at an apt time. You are still a long term holder of that investment! You will hopefully be a bigger investor and been vey smart!
Maybe you are a 'moral' investor, so it does matter to you if you decide not to sell, to protect against loss. That is your decision and your loss!
I invest to make financial gain in companies which I see which have strong potential in sectors which I like. You can do as you wish and I will do as I wish thanks so much.
From here on in, you are filtered!
Doggy100 - think the word was suggested you might look at Avacta - LOL! Having so far made 100% return, not a bad suggestion to you! ;-)
Cheers, Rich
K.Invest, if you knew as much about this company and the progress on every aspect of progress on the POC LFD and the potential from successful AVA6000 as well as the Covid19 virus blocker project, you would not be so negative.
I am very happy with my investment here and I am sure it will be worth many times its current value in months and years ahead. Like Myles, this is a long term holding for me.
And no Atagast, I am not selling any time soon so wind your neck in and get over yourself. My sell of Novacyt, had no effect on the share price. Recently I have quietly bought back in to Novacyt. Its revenue has continued to grow! I have nothing negative to say about NYCT! If you do hold there and not just trolling people then you should do well. However, in reality the growth and potential here on multiple levels is very strong which is why Acacta is my key holing away from funds! My largest buys were here at 38p! Hence why the price jumped very quickly to 60 to 70p. I kept adding there after. No regrets and no reason to sell at all.
Cheers, Rich
The UK is not able to cope with the amount of testing required!
Coronavirus testing system 'falling over' https://www.bbc.co.uk/news/health-54121367
The impact of BAMS and our POC LFD will be huge. We just need some news and a roll out.
It can’t be long for some news and just as was feared the onset of a second spike needs tests and now.
BAMS is overdue!
Cheers Rich
The Introduction:
Avacta is a Biotech company with two operating segments, the Therapeutics operations based at Avacta’s Cambridge site (pre|CISION™ ) and the Diagnostics operations ( Affimer® ) in Wetherby.
The Expertise!
Avacta has two key areas - Affimer® technology a uniquely developed technology which is used as a diagnostic to find virus’s based on a human protein called Stefin A. The Affimer® platform is Avacta’s proprietary therapeutic platform with its intellectual property covered by several patent families.
Projects:
Affimer® technology projects with LG Chem just on licensing can be worth up to $310 million.
ADC project backed by Astra Zeneca for PBD Warheads - loaded affirmer drugs $500 million.
A joint venture in South Korea with Daewoong a leading Korean pharma company, to develop the next generation of cell and gene therapies, incorporating Affimer proteins to enhance the immune-modulatory effects. Avacta holds 45% of the business but the finance is provided by venture capitalists where the market potential is still too large to actually pinpoint as there are NDA's in place so the market information can't be shared. Huge potential!
The huge project with Affimer® technology with Moderna which again will give drug deliveries for mRNA delivery is still progressing. Huge potential!
Affimer® technology to detect Covid19 using Antigen tests the partners are Cytiva (LFD) and Adeptrix (BOMS) with distribution through 4 Mass Spectrometer suppliers (both close to production)
There are existing 5 other Affirmer evaluations progressing, 17 other projects already delivered for evaluation, and a further 7 development projects initiated!
The Expertise:
Avacta’s pre|CISION™ technology can be utilised in a drug conjugate linker or to generate chemotherapy pro-drugs that are only activated in the tumour.
When added to a chemotoxin, the pre|CISION™ substrate prevents the chemotoxin from entering cells and therefore renders it inert until the substrate is cleaved in the tumour microenvironment. Using this pro-drug approach, the systemic exposure to the chemotoxin is dramatically reduced, and the safety and therapeutic window of these powerful anti-cancer treatments are improved.
The projects:
pre|CISION™ partnerships which are looking to start with opportunities in AST, Breast and Ovarian cancer the EU/ US market potential is around $1.5 billion.
Research Opportunities for the reader:
Broker Note: https://mcusercontent.com/d9ebd7c1aa0f3dbc5fab42eca/files/72d24b8a-baa2-4776-a5a7-935a437b37ab/AvactaGroupplc_7_9_2020_FINAL_BG.pdf
The last Presentation:
https://youtu.be/DzoxXCB4or0 - from 1hr 33min 50 seconds
Latest from Avacta: https://avacta.com/news/
and https://avacta.com/investors/documents-presentations/
A good read from a well-known researcher is found here:
https://aimchaos.files.wordpress.com/2020/06/avacta-group-update-ii-part-iii-1.pdf
Investment for 2020 and beyond , it certainly looks good!